Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...

Zoledronic acid 5 mg/100 mL bottle; solution for IV infusion. Paget’s disease of bone is characterized by greatly increased and disorderly bone remodeling. Excessive osteoclastic bone resorption is ...

Infusions might be recommended when oral medications aren’t suitable, potentially improving treatment adherence and reducing gastrointestinal side effects. Zoledronic acid and ibandronate are ...

Bisphosphonate therapy should continue as long as the patient is able to tolerate therapy or until evidence of a substantial decline in performance status. A serum creatinine measurement should be ...

(1) Reclast provides year-long bisphosphonate compliance with a single infusion. Reclast is the only yearly treatment approved to reduce the risk of fractures in areas of the body typically affected ...

Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.